Plasma Exosome-Enriched Extracellular Vesicles From Lactating Mothers With Type 1 Diabetes Contain Aberrant Levels of miRNAs During the Postpartum Period

• Published in: Frontiers in immunology Vol. 12; p. 744509
• Main Authors: Frørup, Caroline, Mirza, Aashiq H, Yarani, Reza, Nielsen, Lotte B, Mathiesen, Elisabeth R, Damm, Peter, Svare, Jens, Engelbrekt, Christian, Størling, Joachim, Johannesen, Jesper, Mortensen, Henrik B, Pociot, Flemming, Kaur, Simranjeet
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 08.10.2021
• Subjects: Adult; Biomarkers - blood; Breast Feeding; Circulating MicroRNA - blood; Diabetes Mellitus, Type 1 - blood; Diabetes Mellitus, Type 1 - genetics; exosomes; Exosomes - genetics; Exosomes - metabolism; extracellular vesicles; Female; Humans; Immunology; miRNAs; Mothers; plasma; Postpartum Period - blood; Postpartum Period - genetics; Pregnancy; small RNA-Seq; type 1 diabetes; type 1 diabetes; extracellular vesicles; miRNAs; plasma; exosomes; small RNA-Seq
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2021.744509

Type 1 diabetes is an immune-driven disease, where the insulin-producing beta cells from the pancreatic islets of Langerhans becomes target of immune-mediated destruction. Several studies have highlighted the implication of circulating and exosomal microRNAs (miRNAs) in type 1 diabetes, underlining its biomarker value and novel therapeutic potential. Recently, we discovered that exosome-enriched extracellular vesicles carry altered levels of both known and novel miRNAs in breast milk from lactating mothers with type 1 diabetes. In this study, we aimed to characterize exosomal miRNAs in the circulation of lactating mothers with and without type 1 diabetes, hypothesizing that differences in type 1 diabetes risk in offspring from these groups are reflected in the circulating miRNA profile. We performed small RNA sequencing on exosome-enriched extracellular vesicles extracted from plasma of 52 lactating mothers around 5 weeks postpartum (26 with type 1 diabetes and 26 age-matched controls), and found a total of 2,289 miRNAs in vesicles from type 1 diabetes and control libraries. Of these, 176 were differentially expressed in plasma from mothers with type 1 diabetes (167 upregulated; 9 downregulated, using a cut-off of abs(log2FC) >1 and FDR adjusted p-value <0.05). Extracellular vesicles were verified by nanoparticle tracking analysis, transmission electron microscopy and immunoblotting. Five candidate miRNAs were selected based on their involvement in diabetes and immune modulation/beta-cell functions: hsa-miR-127-3p, hsa-miR-146a-5p, hsa-miR-26a-5p, hsa-miR-24-3p and hsa-miR-30d-5p. Real-time qPCR validation confirmed that hsa-miR-146a-5p, hsa-miR-26a-5p, hsa-miR-24-3p, and hsa-miR-30d-5p were significantly upregulated in lactating mothers with type 1 diabetes as compared to lactating healthy mothers. To determine possible target genes and affected pathways of the 5 miRNA candidates, computational network-based analyses were carried out with TargetScan, mirTarBase, QIAGEN Ingenuity Pathway Analysis and PantherDB database. The candidates showed significant association with inflammatory response and cytokine and chemokine mediated signaling pathways. With this study, we detect aberrant levels of miRNAs within plasma extracellular vesicles from lactating mothers with type 1 diabetes during the postpartum period, including miRNAs with associations to disease pathogenesis and inflammatory responses.